/IMVIF

IMVIF Stock - IMV Inc.

Q: What is the analyst price target for IMVIF?

Analyst price target information is not currently available for IMVIF.

Q: What is IMVIF's market cap?

Market capitalization information is not currently available for IMVIF.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IMVIF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.25

52W High$0.01

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	$3,158	$45,498	$60,038
Gross Profit	$-962,298	$-536,239	$3,158	$45,498	$60,038
Gross Margin	N/A	N/A	100.0%	100.0%	100.0%
Operating Income	$-38,671,513	$-40,231,855	$-35,279,167	$-22,350,491	$-16,015,522
Net Income	$-36,485,694	$-36,267,053	$-27,435,609	$-21,102,756	$-16,060,184
Net Margin	N/A	N/A	-868765.3%	-46381.7%	-26750.0%
EPS	$-4.37	$-4.89	$-4.55	$-4.25	$-3.67

Company Overview

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Visit Website

Earnings History & Surprises

IMVIF

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.90

Q4 2022

EPS Surprise History

Q3 21

No data

Q4 21

No data

Q1 22

No data

Q2 22

No data

Q3 22

No data

Q4 22

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2022	Dec 31, 2022	—	$-0.90	—	—
Q3 2022	Sep 30, 2022	—	$-1.02	—	—
Q2 2022	Jun 30, 2022	—	$-1.19	—	—
Q1 2022	Mar 31, 2022	—	$-1.30	—	—
Q4 2021	Dec 31, 2021	—	$-1.42	—	—
Q3 2021	Sep 30, 2021	—	$-1.31	—	—